The microsatellite instable (MSI) subset of colorectal cancer exhibits an active Th1/CTL immune microenvironment, probably due to recognition of a high number of tumor neoantigens. However, the high expression of checkpoint molecules PD-1, PD-L1, CTLA-4, LAG-3, and IDO in MSI colorectal cancer distinguishes MSI from microsatellite stable colorectal cancer and creates an immunosuppressive microenvironment that may help MSI tumors evade immune destruction by the infi ltrating immune cells. Though colorectal cancer does not have a good response rate to PD-1 pathway immunotherapy, these results suggest that the MSI subset of colorectal cancer is a particularly good candidate for checkpoint immunotherapy. Cancer Discov; 5(1);
Microsatellite instable (MSI) colorectal cancer comprises approximately 15% of sporadic colorectal cancer and most familial colorectal cancer, whereas microsatellite stable (MSS) colorectal cancer comprises the remainder ( 1 ) . MSI is typically diagnosed by the variable length of DNA microsatellites (mononucleotide and dinucleotide repeats; ref. 1 ) . This variation is a consequence of epigenetic silencing or mutation of DNA mismatch repair genes ( 1, 2 ) . Cells with abnormal mismatch repair function accumulate DNA replication errors, and novel microsatellite lengths are created. Impaired DNA mismatch repair facilitates insertions or deletions that can be frame-shift mutations as well as single-base mismatches that can be point mutations in coding regions. MSI allows mutations to be accumulated at many times the normal rate and facilitates MSI neoplastic progression (ref. 1 ; Fig. 1A ).
The high mutational load in MSI tumors also creates many tumor-specifi c neoantigens, typically 10 to 50 times those of MSS tumors ( 3 ) . Some of these neoantigens will be processed, presented on MHC, and recognized as foreign by T cells ( Fig. 1A ) . In particular, frame-shifted proteins should be a rich source of neoantigens. This high neoantigen burden might be one explanation for the high level of tumor-infi ltrating lymphocytes (TIL) and lymphocytic reaction in MSI tumors observed in many previous studies ( 1 ) . MSI tumors have a better prognosis than MSS ( 2 ), and the higher level of neoantigens in MSI may contribute to better survival via more robust immunoediting of MSI ( 4 ) .
In this issue of Cancer Discovery , Llosa and colleagues ( 3 ) analyzed primary sporadic colorectal cancer from patients free of prior chemotherapy and found that a subset of primary sporadic colorectal cancer displayed high infi ltration of activated CD8 + cytotoxic T lymphocytes (CTL) as well as activated Th1 cells with IFNγ production and the Th1 transcription factor T-bet. Th17 or Th2 populations were not expanded. They determined that nearly all of the tumors of this subset were MSI colorectal cancer.
Despite a robust Th1/CTL microenvironment, MSI tumors are not naturally eradicated, though some incipient MSI tumors may be eradicated and never seen as colorectal cancer. with a higher affi nity than CD4. LAG-3 is important in controlling CD8
+ T-cell activity within target organs. LAG-3 is also required for maximal regulatory T-cell function and can inhibit DC function by engaging MHC II on DC. IDO is an enzyme that catalyzes the degradation of the essential amino acid tryptophan to kynurenine. Production and secretion of IDO are induced by IFNγ and IL10 . In the tumor microenvironment, IDO is produced by tumor cells, antigenpresenting cells (APC), tumor-associated myeloid-derived suppressor cells (MDSC), and tumor-associated macrophages (TAM) in response to these infl ammatory signals. High levels of IDO reduce tryptophan levels and create kynurenine, both of which contribute to suppression of T-cell activity and are a potential mechanism for immune tolerance to tumor antigens ( 5 ) .
In melanoma and many tumor types, the interface between the wave of infi ltrating lymphocytes and the tumor is characterized by PD-L1 expression on the tumor cells ( 6 ) . This is believed to be a consequence of T-cell recognition of the tumor ( 7 ); however, there is not general agreement on human MDSC markers, and Llosa and colleagues did not pursue this point. They also explored the lack of PD-L1 expression on the MSI tumor cells and found that in response to IFNγ, both MSI and MSS colorectal cancer cell lines modestly upregulated PD-L1 and HLA-DR in comparison with the robust upregulation on melanoma and other cancer cell lines ( 3 ). They speculated that this might be a consequence of impaired STAT1 signaling, but changes in IFN receptor might also be involved ( 3 ) .
One mystery is why the high load of neoantigens does not lead to immune eradication of MSI colorectal cancer. MSI tumors most often arise on the right side of the body in the proximal colon, and recent work has shown that the gut microbiota contributes to the development of colorectal cancer. The abundance of Fusobacterium species, particularly F. nucleatum , in tumor tissue has been shown to be associated with MSI colorectal cancer ( 8 ) . Fusobacterium proteins can selectively recruit tumor-infi ltrating myeloid cells and inhibit T-cell proliferation ( 9 ) . Fusobacterium may facilitate upregulation of checkpoint ligands such as PD-L1 in these recruited This still leaves a great need for effective immunotherapies in the remaining 95% of stage IV colorectal cancer. As the checkpoint blockade molecules were discovered by their effects on immune tolerance, this suggests we need to deepen our understanding of the specialized mechanisms of gut immune tolerance to identify additional targets for colorectal cancer immunotherapy.
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